Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2026 | Left atrial appendage closure for stroke patients who cannot take long-term anticoagulation

Ana Catarina Fonseca, MD, PhD, MPH, University of Lisbon, Lisbon, Portugal, discusses the approach to left atrial appendage closure for stroke patients who cannot take long-term anticoagulation, highlighting the lack of clear data from clinical trials to support its benefit. Dr Fonseca notes that the decision should be made on a case-by-case basis, taking into account the patient’s life expectancy, frailty, and individual characteristics. This interview took place at the 18th World Stroke Congress (WSC) in Seoul, Korea.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Initially, when we thought about left atrial appendage occlusion, it was a very good idea taking into account that most thrombi are formed in left atrial appendages, about 90%. So the idea was, if we exclude left atrial appendages, we can decrease the number of thrombi that are formed. So that can fix the problem, right? If a patient’s atrial fibrillation cannot be anticoagulated, maybe this is a good alternative...

Initially, when we thought about left atrial appendage occlusion, it was a very good idea taking into account that most thrombi are formed in left atrial appendages, about 90%. So the idea was, if we exclude left atrial appendages, we can decrease the number of thrombi that are formed. So that can fix the problem, right? If a patient’s atrial fibrillation cannot be anticoagulated, maybe this is a good alternative. Actually, you don’t really have data from clinical trials that have actually shown this, that this is true. There’s a clinical trial, CLOSURE-AF, that included patients with a very high risk of bleeding, but those patients could be anticoagulated. 85% of patients actually were anticoagulated. So actually, we did not adopt the data from clinical trials. There’s a registry that was done by Professor David Werring, which included patients that had microbleeds or previous endocrine hemorrhage, and he didn’t want to use anticoagulants. And he showed in this registry, that’s mainly observational data, right, that it’s possible to perform it and it was not associated with an increased number of events, either ischemic events or hemorrhagic events. So it’s something that you can propose to the patient, but you have to tell him that there’s very little data actually at the moment that proves that this procedure can actually show a clear benefit. Also, another thing that you have to take into account, because it is still an invasive procedure, you have to take into account what’s the patient’s life expectancy. So what some of the data that we have from culture, for example, has shown that those patients, because they have increased frailty or also have a higher probability of dying from concurrent diseases, right? So you have to take into account actually what’s the life expectancy of the patient, see the patient himself, what are his characteristics, and also explain to him that we don’t have clear data, that’s a possible intervention that you can do in that.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.